Actively Recruiting
Cognitive Control Mechanisms in Older Adults
Led by Hebrew University of Jerusalem · Updated on 2024-10-08
42
Participants Needed
1
Research Sites
82 weeks
Total Duration
On this page
Sponsors
H
Hebrew University of Jerusalem
Lead Sponsor
U
University of Melbourne
Collaborating Sponsor
AI-Summary
What this Trial Is About
The prevalence of depressive symptoms in older adults is on the rise, affecting 13 to 37% of older adults globally. These symptoms significantly impact health, increasing the risk of dementia and cognitive decline, and impairing daily functioning and quality of life. Reduced cognitive control (CC) is a key factor contributing to depressive symptoms, affecting 40% of adults with such symptoms. Despite this, over half of affected adults do not respond well to available treatments. Computerized cognitive training (CCT) has shown efficacy in improving CC but its impact on daily functioning is limited. The Cognitive Orientation to Occupational Performance (CO-OP) approach has demonstrated promise in improving daily functioning, as measured by occupational performance (OP). We propose a novel intervention, GOLD-Cog+, combining CCT and CO-OP, to address CC and functional deficits in older adults with depressive symptoms.
CONDITIONS
Official Title
Cognitive Control Mechanisms in Older Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Depressive symptoms with Patient Health Questionnaire (PHQ-8) score of 5 or higher
- Healthy cognition with Montreal Cognitive Assessment (MoCa) score of 20 or higher
- Able to sign and agree to participate in the study
- Basic technological skills to use a tablet based on self-report
- Adequate sight and hearing (with assistive technology if needed) to use a tablet and participate in a small group
- Able to fluently read, speak, and understand Hebrew or English
You will not qualify if you...
- Any neurodegenerative disorder such as Mild Cognitive Impairment, Dementia, or Parkinson's disease (self-reported)
- Psychiatric disorders other than depression or anxiety, including Schizophrenia, Bipolar, or Psychotic disorders (self-reported)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Computerized Neurotherapy Lab, School of OT, Hebrew University, Mt. Scopus Campus
Jerusalem, Israel
Actively Recruiting
Research Team
E
Eliane Gefen, MsC
CONTACT
M
Mor Nahum, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here